Background:  Psilocybin is naturally occurring tryptamine alkaloid, with psychoactive properties, produced by numerous fungi.  There is preliminary clinical evidence supporting the therapeutic potential of psilocybin, including phase 3 trials for treatment-resistant depression. The approval of psilocybin as a medical treatment for depression in certain jurisdictions underscores the need for a balanced and scientific understanding of psilocybin therapy. A contemporary appreciation of psychiatrists’ knowledge and attitudes to the rapidly evolving field of psilocybin therapy is a vital component in this process.    Objectives:  To assess the knowledge and attitudes of (Irish) psychiatrists to the therapeutic use of psilocybin, and to explore factors that influence these attitudes.    Methods:  An anonymised 28-item questionnaire was designed and distributed via an online link.  Data were collected using Qualtrics and analysed using SPSS Statistics. Results:  151 psychiatrists completed the questionnaire. Of these, 82% agreed that psilocybin therapy shows promise in the treatment of psychiatric disorders, ranging from 80% in depression to 9% in psychotic disorders. 15% of the total sample reported at least one concern qualitatively including lack of evidence, cost and accessibility.     Conclusion:  Overall, attitudes to the therapeutic potential of psilocybin therapy were mostly favourable. Younger psychiatrists tended to hold more positive attitudes towards the potential use of  psilocybin therapy as a treatment for specific psychiatric disorders and demonstrated a willingness to refer patients if it was an evidence-based, licenced therapy.  More senior psychiatrists were less willing for psilocybin with psychological support to be granted medical treatment status, even if supported by evidence from clinical trials.